Answers are grounded in this paper and cite their sources.
Treatment of childhood acute lymphoblastic leukemia (ALL) has made tremendous strides over the past 20 years, but has been complicated by the induction of secondary tumors after some regimens. The cumulative incidence of therapy-related myeloid leukemia and myelodysplastic syndrome (referred to collectively as t-ML) varies widely among treatment protocols, from 1% to 12%.
No takes yet. Share an insight, caveat, or question.
Mary V. Relling (2009) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: